Key points: Among invasive mould infections (IMIs), invasive aspergillosis is the commonest IMI in Asia. Steroid use and neutropenia are important risk factors, but diabetes is a common underlying condition, particularly in patients without history of steroid exposure or neutropenia. 
Introduction
There is increasing international awareness of invasive mould infections (IMI). This is related in part to the explosion in the number of immunocompromised persons, attributed to successes in transplantation and chemotherapy. In addition, the antemortem diagnosis of mould infections has improved, at least in part, after the introduction of new techniques such as the galactomannan (GM) assay, the beta-D-glucan (BDG) assay, and various polymerase chain reaction (PCR) assays. 1 The diagnosis of IMI in immunocompromised persons has, naturally, received the greatest attention. In recent years, international consensus guidelines on the diagnosis of IMI have been developed and refined, and their use has become standard in the literature.
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The treatment of mould infections has also been transformed by the advent of new antifungal agents such as new triazoles, echinocandins and lipid preparations of amphotericin B. Investigators in the field have reported a decline in the mortality associated with IMI and have attributed it to the use of these newer agents. 5, 6 It is noteworthy that the studies that formed the basis for these comments have come almost exclusively from American and European centers. From epidemiologic studies, to studies testing new diagnostic kits, to drug trials, to algorithmic approaches to IMI-Western centers have dominated the literature.
In comparison, data from Asian countries are scarce, although individual centers have reported high incidence with varied epidemiology. This has been highlighted by regional investigators. 7 Transnational papers are rare, and there is no systematic, intercountry study of the epidemiology of IMIs in Asia. No paper has attempted to provide an overview of IMIs from the clinician's perspective. A comprehensive Japanese report based on autopsy data reported an increasing rate of Aspergillus infections but covered all types of fungal infections including yeasts and by its very nature was limited only to autopsy material. 8 An Indian report covered invasive pulmonary aspergillosis over a 12-year period but was also an autopsy series and was based on only 39 patients from one center. 9 A recent, large, single-center Taiwanese study of invasive aspergillosis (IA) noted a significant increase in incidence between 2000 and 2009, but positive cultures were used to identify cases, and hence the report is likely incomplete because it did not include culture-negative cases. 10 A recent Thai and
Bahraini series on IA also provide snapshots of the problem at single tertiary centers. 11, 12 Finally, an international, prospective study of invasive fungal infections found that Aspergillus spp. were associated with the majority of cases and had an overall 30-day mortality of 22.1%. 13 However, this study was limited to patients with hematologic malignancies. Hence, to date, there has been no large-scale, systematic, international study of the epidemiology of IMIs in Asia. The present multicenter, retrospective study of IMIs at five centers in five countries across Asia was therefore initiated, under the auspices of the Asia Fungal Working Group (a working group of the International Society for Human and Animal Mycology). The primary objective was to determine the incidence and clinical determinants of IMIs in an Asian context. Secondary objectives were to determine the demographics and risk factors for IMI; the types of moulds responsible for IMIs; physician practices in the management of patients with IMIs; and patient outcomes.
Methods

Study design
This was a 1-year, retrospective study of IMIs at five centers in five Asian countries, one each from Bangkok (Thailand), Beijing (China), Chandigarh (India), Singapore, and Taipei (Taiwan). All participating sites were required to meet the following criteria: maintain International Classification of Diseases (ICD) coding and data on the total number of discharges and deaths; manage hematology and transplant patients; perform high-resolution computed tomography (CT) scans; have a microbiology/mycology laboratory that performs isolation and identification of fungi to at least genus level; and have histopathology facilities.
Only diagnoses of an IMI made between 1 January and 31 December 2012 were considered. Ethics approval for the study was obtained from the Institutional Review Board of each site.
Initial patient screening
Potentially eligible patients came from three possible sources: discharge/death diagnosis, microbiology/mycology laboratory records, and histopathology laboratory records.
With regard to discharge/death diagnoses, all cases that carried an IMI as a discharge diagnosis were assessed. One of the following ICD-9 codes was required for eligibility within the study: 117.3 (Aspergillosis); 117.6 (Allescheriosis); 117.7 (Zygomycosis or Mucormycosis); 117.8 (Phaeohyphomycosis, i.e., infection with dematiaceous fungi); 117.9 (other and unspecified mycosis); and 118 (opportunistic fungi, i.e., infection of skin, subcutaneous tissues, and/or organs by a wide variety of fungi generally considered to be pathogenic to compromised hosts only, e.g., infection by species of Alternaria, Drechslera, Fusarium).
For microbiology/mycology data as a source, appropriate laboratory records were reviewed. The case files of patients with evidence of mould infection (e.g., hyphae seen on smears, positive culture for a mould) were then assessed for eligibility within the study.
For histopathology, case records of patients with histology/cytology showing septate hyphae invading tissue were reviewed to assess eligibility within the study.
Study subjects
The electronic and paper records of potentially eligible patients identified by one of the three methods described above were assessed against the study inclusion criterion, which required diagnosis of a proven or probable IMI, based on published definitions. For patients with sinusitis from the Indian center, a modification of the EORTC/MSG guidelines was applied. Diabetes mellitus (DM) was accepted as a host criterion, and the clinical criteria were modified such that pain alone was inadequate; there had to be a black eschar or radiologic evidence of extension across bone. EORTC/MSG mycologic criteria had to be met.
Patients were excluded if they had endemic mycoses (e.g., histoplasmosis), sporotrichosis, penicilliosis, yeast infections, allergic fungal diseases like allergic bronchopulmonary aspergillosis, or infection limited to the skin or eye.
Assessments
The case records of eligible patients were reviewed and the following data collected: demographic information; host factors (defined according to EORTC/MSG criteria) and underlying conditions that may have predisposed them to acquiring an IMI; sites of involvement; clinical manifestations; radiologic features (in patients with lung involvement); laboratory investigations, including fungal microscopy, cytologic examination, fungal cultures, and serum galactomannan (GM); empiric/prophylactic and definitive treatments (empiric use of antibiotics/antifungals was defined as administration before a microbiologic result was known); and 90-day mortality.
Assessment was also made of risk factors for 90-day mortality, and of the association between two specific host factors (recent history of neutropenia and prolonged use of steroids) and other patient-related variables: age; DM; fever; lung involvement; skin/subcutaneous involvement; disseminated disease (defined as involvement at two or more noncontiguous sites, with involvement of lung and sinus not taken as disseminated but classified as a separate category 14 ); surgery; and survival at discharge.
For the purposes of this study, 'any lung involvement' was defined as lung infection alone, as part of a lung plus sinus syndrome, or as part of disseminated disease. The term 'sinus-related' refers to cases with sinusitis only, sino-orbital disease, sino-orbito-cerebral disease, or sino-cerebral disease. Cases of aspergillosis included those that were culturepositive for Aspergillus, as well as those positive for GM (unless they grew a non-Aspergillus mould).
Appropriate data were recorded electronically and sent to the collating center in Singapore, where they were reviewed for completeness and internal consistency and subsequently analyzed. Whenever doubts existed (e.g., discrepant information), clarification was sought from individual sites.
Statistical analyses
Data were extracted for statistical analysis using SAS Version 9.3 for Windows (SAS, Inc. Cary, NC USA). Data are The association between recent history of neutropenia/prolonged use of steroids and other patient-related variables was analyzed using the two-sample t-test for continuous variables and the χ 2 /Fisher exact test for categorical variables.
Multiple logistic regression analysis was also carried out to determine risk factors for death 90 days after diagnosis. Variables with P-value < 0.20 in a univariate analysis, as well as clinically significant variables that did not reach statistical significance, were incorporated in the initial model. Multiple logistic regression models were then built, yielding the best prediction using a stepwise selection approach.
Statistical significance was set at P < .05.
Results
Aggregated results across all five centers are presented. Additional data are available in Supplementary Material 1, and data from individual centers are provided in Supplementary Material 2.
Patient characteristics and demographics
A total of 185 case report forms were received. Of these, 30 were rejected because they did not meet the inclusion/exclusion criteria. Hence, 155 cases were included in the present analysis. 66 came from Thailand, 40 from Taiwan, 23 from Singapore, 14 from China, and 12 from India (Table 1 ). IMI incidence rates varied between 0.0242 and 0.2631 per thousand patient-days (Table 1) . Among the 155 included cases, the median age was 54 years (range, 4-84 years) and 74 (47.7%) were male. A total of 74 (47.7%) had proven IMI. The remaining 81 patients (52.3%) had probable IMI: 74 based on EORTC/MSG criteria (including four with sinusitis from India, using modified criteria), five by the Blot criteria, and two by the Bulpa criteria (Supplementary Material 2). Host factors and underlying conditions that may have predisposed patients to acquiring an IMI are provided in Table 2 . The most common host factors were prolonged use of corticosteroids (n = 61; 39.4%) and a recent history of neutropenia (n = 60; 38.7%). Among the underlying conditions, DM was the most common (n = 48; 30.9%), followed by acute myeloid leukemia (AML; n = 30; 19.4%) and rheumatologic conditions (n = 18; 11.6%).
The 48 DM cases were further analyzed. Twenty-eight patients had other underlying conditions; in the remaining 20 cases (12.9% of the entire study population), DM was the only underlying condition, of which 14 had a proven and six had a probable IMI (Table 3) .
Clinical presentation
Classification of IMIs according to the sites of involvement are provided in Table 4 . The lung was the most commonly involved site, affecting 122 patients (78.7%), following by sinus-related cases (n = 17; 11.0%). Pulmonary involvement was the sole manifestation of IMI in 95 cases (61.3% of the entire study population). Clinical manifestation data were also collected (Table 5) . Fever was the most frequent (n = 107; 69.0%), and various respiratory symptoms were also common, particularly cough (n = 78; 50.3%) and breathlessness (n = 77; 49.7%). Pleuritic chest pain was recorded in 25 patients (16.1%), all of whom had aspergillosis. a Expressed as percentage of total number of subjects (n = 155). b In one case, bone was also involved. c Brain (n = 1), osteoarticular (n = 1), kidney (n = 1), peritoneal dialysis fluid (n = 3), ear (n = 1). d Cardiac + brain (n = 1), cardiac + lung + sinus (n = 1), lung + brain (n = 4), lung + liver (n = 1), lung + liver + kidney (n = 1), lung + sinus + brain (n = 1), lung + sinus + joint (n = 1), lung + skin (n = 4), lung + sinus + appendix ( = 1). IMI, invasive mould infection.
Radiologic and laboratory investigations
Radiologic features of the patients with lung involvement (n = 122) are shown in Table 6 . In almost half of cases, a CT scan of the thorax showed a mix of features (n = 57; 46.7%). The halo sign was seen in only 5 patients (4.1%).
On chest X-ray, consolidation (n = 37; 23.9%) was slightly more common than nodules (n = 34; 21.9%). Ninety-five patients (61.3%) had specimens submitted for fungal microscopy; of these, 51 (53.7%) were positive for hyphae (Supplementary Material 1) . In addition, 92 patients had specimens submitted for cytologic examination, and 46 (50.0%) were positive for hyphae (Supplementary Material 1). Sinus aspirates tended to have the highest yield for both types of smears.
With regard to fungal cultures, these were performed for 125 subjects (80.6%), with 88 (70.4% of 125) recording positive results (Table 7) . Bronchoalveolar lavage fluid was the most commonly cultured site (n = 65), and contributed to 33 of the 88 positive results (37.5%). A lung biopsy was performed in 21 cases and yielded mould by culture in 14 instances (66.7%). All 15 patients with sinusitis had a positive culture for a mould from sinus aspirate ( Table 7) .
The most commonly cultured mould was Aspergillus, accounting for 63 (71.6%) of all 88 positive cultures (Table 7) . A. fumigatus was the leading Aspergillus species. Mucormycetes were responsible for nine infections (10.2%).
The distribution of mould species by site of involvement is shown in Figure 1 . Aspergillus was the dominant species in pulmonary, sinusitis, disseminated & other cases. By contrast, soft tissue infections were caused by a variety of other moulds. Skin and soft-tissue involvement was a significant predictor of a non-Aspergillus mould (P < .001) (Supplementary Material 1). A total of 111 patients were tested for serum GM, and this was positive in 75 cases (67.6%). However, in two cases, it was probably a false-positive, as cultures grew mucormycetes. Of the positive serum GM results, 52% came from neutropenic patients.
Treatment and outcomes
Empiric antifungal treatment was given to 94 patients (60.6%), and 98 (63.2%) received definitive treatment consisting only of antifungal agents ( Table 8 ). The most commonly used antifungal for empirical therapy was amphotericin B deoxycholate (AMB), and for targeted therapy was voriconazole (VCZ). Ninety-day mortality among the 155 patients in this study was 32.9%. By univariate analysis, risk factors for 90-day mortality included older age, disseminated disease, prolonged use of steroids, exposure to a T-cell suppressant, a rheumatologic condition, higher serum GM, empiric treatment with fluconazole, and short treatment duration. Using multiple logistic regression analysis, disseminated disease, a rheumatologic condition, and higher serum GM levels were found to be potential predictors of mortality (Supplementary Material 1) .
Association between key host factors and other variables
An analysis was performed to examine the association between the two most common host factors (prolonged use of corticosteroids and a recent history of neutropenia) and various patient variables, for example, demographics and underlying conditions (Table 9) .
A recent history of neutropenia was found to be significantly associated with younger age, absence of DM, fever, and lung involvement. Prolonged use of steroids was significantly associated with lung involvement, absence of surgery, and death before discharge. When these two host factors were combined, the presence of either recent neutropenia or prolonged use of steroids correlated with a number of variables: absence of DM, fever, lung involvement, absence of surgery, and death before discharge (Table 9) .
Discussion
To the best of our knowledge, this 1-year, retrospective study is the first multicenter Asian report on IMI that is not limited to specific patient groups or diagnostic methods. IMI incidence rates varied between 0.0242 and 0.2631 per thousand patient-days across the five centers. However, the actual burden of IMI may be higher. Thirty out of 185 case report forms submitted (16.2%) were excluded-around a third because they did not meet the EORTC/MSG criteria. There was a particularly high rejection rate of submissions from India, possibly due to high levels of familiarity with the clinical presentation of IMI, which may have led to necessary interventions being made with less effort devoted to proving the diagnosis using published criteria. This contrasts with Singapore, where the proportion of proven cases was the highest. The need to prove the diagnosis may reflect Singapore's more litigious society, a more questioning populace, 15 and a payment system in which patients are effectively using 'their own' money. The difficulty of fulfilling the inclusion criteria for clinical studies of this type has been highlighted previously, and it has been suggested that the EORTC/MSG criteria are too restrictive. 16, 17 In the present work, some adjustments were made. In particular, recognizing that sinocranial mycosis is well documented in India; the EORTC/MSG criteria were modified to include DM as the sole host criterion. However, to be accepted, cases still had to have bone erosion or extension to an adjacent site. [18] [19] [20] This need to modify current criteria to allow the inclusion of patients with clinically obvious fungal rhinosinusitis highlights an important gap. Strictly speaking, published criteria in this area are merely a means of categorizing fungal rhinosinusitis and can only be applied after histopathology is available. 21, 22 Hence, there is a need for consensus standards for the clinical diagnosis of IMI of the sinuses, perhaps modeled on the EORTC/MSG criteria. A key finding from the present work was that DM was an important underlying condition, found in around a third of the subjects in this study. Previous reports have also noted this link. 12, 23 For example, patients with diabetic ketoacidosis may be particularly susceptible to rhinocerebral mucormycosis. 24 Furthermore, in a recent Indian series, uncontrolled DM was a risk factor for this condition, even in the absence of ketoacidosis. 25 The large number of cases from India has been attributed to the high prevalence of DM and a local love of sweets. 25 However, DM has also been recognized as a risk factor for IMI outside India. [26] [27] [28] Indeed, a Thai IA series found DM as an underlying condition in 17% of cases.
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Of the 48 patients with DM in this study, almost half (20) had no other underlying condition. This aligns with a small Thai study, which noted DM in all patients with sinusrelated IMI and found that half had no other underlying condition. 26 Nivoix and coworkers have also highlighted the role of 'concomitant DM' as a risk factor for IA. In addition, DM was also common in patients with more 'classical' underlying conditions, such as hematologic malignancies. This supports the possibility that the presence of two or more risk factors/predisposing conditions may precipitate the occurrence of IMI in persons who do not meet current consensus criteria. 27 In the study, the most common EORTC host factors were prolonged use of corticosteroids and a recent history of neutropenia. These were observed less frequently among patients with DM but more often in those with fever or lung involvement. Indeed, > 90% of neutropenic IMI patients had pulmonary involvement; by contrast, among 33 IMI subjects with only extrapulmonary disease, 87.9% were non-neutropenic. More important, non-neutropenic patients also tended not to have fever. Hence, clinicians should consider IMI in patients with the appropriate presentation, even if they are afebrile and do not have classical risk factors. In our series, 11.6% of patients had an underlying rheumatologic condition. As these individuals are typically treated with immunosuppressive agents, they may have an elevated risk of opportunistic infections, including IMIs. A recent study suggested that rising use of anti-tumor necrosis factor agents may increase the risk of IMI in patients with rheumatologic conditions, 30 although only 3.9% of patients had received prior monoclonal antibody therapy in the present work. Previous studies have typically not found high IMI rates among patients with rheumatologic conditions. For example, in an analysis of 5,604 patients with juvenile systemic lupus erythematosus (SLE), only 2.1% were diagnosed with IA. 31 Kim et al. found a similarly low incidence of IMIs in a review of 3,159 individuals with SLE or rheumatoid arthritis. 32 Our study shows that patients with rheumatologic conditions may constitute a significant proportion of patients with IMI. Almost 80% of IMI cases had lung involvement, and more than 60% were only in the lung. Patients with IMI involving the lungs had a wide range of CT features, which aligns with findings from a Korean study. 33 Nucci and colleagues have proposed a new category of aspergillosis called Table 9 . Association between recent history of neutropenia and/or prolonged use of steroids, and other patient variables. 'IA without prespecified radiologic criteria' and shown that these patients have comparable clinical characteristics and outcomes to those with EORTC/MSG proven and probable IA. 16 Girmenia et al. have reported similar experiences.
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The present work adds further weight to the suggestion that IMI should not be ruled out in patients with a suspected infection whose chest features on CT do not fit the EORTC/MSG criteria. As expected, Aspergillus spp. were responsible for the majority of IMIs. A. fumigatus was the most commonly isolated species, although A. flavus was as common in India. This has been noted previously 7 and may relate to the hot climate. 34 Indeed, an aerobiological survey in Delhi found that A. flavus was the most common Aspergillus. 35 A. flavus was also the predominant Aspergillus in a Sudanese study. 36 The predominance of A. flavus in sinusitis has been attributed to its large conidia, 34 which may affect pathogenesis. However, the role of climate is less straightforward, given that Singapore and Thailand are hot yearround and yet A. fumigatus remains the leading mould, as in temperate areas. Interestingly, at 20 and 30
• C, the germination rates of various species of Aspergillus have been found to be similar, but at 41
• C the germination rate of A.
fumigatus was enhanced, whereas that of A. flavus fell by 45%. 37 The Delhi survey noted that mould concentrations in the air were lowest in the dry and hot summer months and rose at times of precipitation. 33 The authors suggested that high humidity was a factor, and it could also contribute to the Aspergillus isolation pattern in the present work. The most commonly used antifungal for empirical therapy was AMB, possibly owing to its lower cost. However, there were large differences between locations, with no use of AMB for empiric therapy recorded in the Chinese and Singaporean centers, largely due to nephrotoxicity concerns. The frequency of empiric therapy was also variable, possibly due to heightened suspicion at some centers (e.g. Thailand, India), unexpected culture results (e.g. peritoneal dialysis fluid in Singapore), and a small contribution from AML and HSCT cases in other centers (Singapore, China).
The 90-day mortality rate (32.9%) is an improvement on historical data. For example, a review of case series published between 1995 and 1999 placed the overall casefatality rate for IA at 58%; 38 it was even higher in HSCT recipients (86.7%) and in patients with disseminated disease (88.1%). However, mortality rates appear to be declining. The TRANSNET report, covering the years 2001-2006, noted a 1-year survival of 59% in solid organ transplant recipients with IA and of 61% in patients with nonAspergillus moulds. 39 An Italian report, limited to IA in patients with acute leukemia, demonstrated a falling mortality rate, from 48% in a 1987-1998 cohort, to 38.5% in a 1999-2003 cohort, to 13% in those studied post-2006. 5 In our series, the 90-day survival of aspergillosis cases among acute leukemics was 59.5%. The Italian group attributed the improving survival rates to prompt diagnostics and possibly antifungal prophylaxis. 5 The authors of an Austrian study attributed improved survival of IA patients to increased use of VCZ. 6 Several factors may contribute to the survival rates in the present series: all participating sites were tertiary centers with experience in managing infections in immunocompromised hosts; the adoption of newer diagnostic techniques, such as the GM assay; and the use of newer agents, such as VCZ. The presence of a substantial number of patients without recent neutropenia or prolonged steroid use as risk factors (n = 56/155) may also have contributed, as these individuals were more likely to survive to discharge. These 'nonclassical' hosts often had unusual conditions (e.g., peritonitis or soft tissue infection), in which a specific intervention (e.g., removal of a Tenchkoff catheter) likely contributed to a positive outcome. The study had several limitations. Most importantly, it was retrospective in design. However, given scarce manpower and the need to include subjects from many sources (positive GM, culture, histopathology), retrospective review of microbiology, and histopathology logs was an effective means of ensuring consecutive cases were recruited. The study was also relatively short in duration, spanning 1 year (2012). Hence, its findings may reflect the peculiarities of the different centers in that period. For example in Taiwan, typhoons are known to increase fungal colony counts in the air, and thus local weather patterns may have affected the results. 40 However, 2012 was considered an average year for typhoons. 41 Despite these limitations, this study provides a valuable insight into IMIs from five centers in five different Asian countries, a new milestone for the region. Looking ahead, as electronic medical records in hospitals become more sophisticated, this may facilitate common standards in data archives and data collection across hospital centers. Subsequently, conducting multicenter studies may be made more efficient along with augmented data quality. This highlights the value of pioneering cross-country collaboration research-providing a basis for enhanced collaboration in future, aided by technology. In conclusion, IMI appears to a significant clinical problem and occurs in a wide variety of hosts. Invasive aspergillosis was the most common infection. DM (particularly in patients without a history of steroid exposure or recent neutropenia) and rheumatologic diseases were frequently observed underlying conditions, highlighting the importance of appropriate surveillance in these individuals. Unsurprisingly, there were important differences between centers in the types of moulds isolated, the disease spectrum, and the clinical management of suspected and confirmed cases.
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